Mike Gresser received his Ph.D in Biochemistry in 1976 from Brandeis University, and completed postdoctoral studies at the Molecular Biology Institute at UCLA on the mitochondrial and chloroplast proton translocating ATP synthases. In 1980 Mike joined the Department of Chemistry at Simon Fraser University in British Columbia, where he served as Assistant Professor, Associate Professor, and Professor of Chemistry. In 1988 Mike joined Merck & Co., Inc. as Director of Biochemistry at the Merck Frosst Center for Therapeutic Research, and was eventually promoted Executive Director of Biochemistry and Molecular Biology. In 2000 Mike joined Amgen, where he remained until 2006. While at Amgen he served as VP, Research for Inflammation and later as Head of Neuroscience Research and Inflammation Research. Subsequently, Mike also served as the Interim Chief Scientific Officer at Oxford BioTherapeutics between 2009 and 2010, CSO at the Myelin Repair Foundation, and is currently a Visiting Scholar at the Molecular Biology Institute at UCLA as well as Chief Scientific Officer at ImmunGene.
Scientific Advisory Board
Tom Boone is an experienced bench scientist and manager having served a 28 year career with Amgen. Tom received his graduate degrees from UC Davis and UCLA and joined Amgen as a research associate cloning and sequencing genes including G-CSF (Neupogen). During the late 80’s and throughout the 1990’s Tom worked in process development as a scientist and director and developed or oversaw the development of many of the processes implemented at Amgen including the Neupogen process. Tom then headed the expression, purification, and characterization groups within Amgen's research group which went on to become the Protein Science group. Tom retired from Amgen in 2009 as VP, Protein Sciences overseeing a biologics R&D team of over 300 researchers across five sites. Tom currently serves as Senior VP, Protein Sciences at Oxford BioTherapeutics.
Dr. Davis, currently President and CEO of Angelica Therapeutics, was a founder and the Chief Scientific Officer for Abgenix, Inc., where he led the development of the XenoMouse® technology, was involved in the research and development of Vectabix®, a fully human monoclonal antibody approved for colorectal cancer, and guided the discovery of 11 other antibodies currently in clinical trials. Prior to founding Abgenix, Dr. Davis was a faculty member at the University of California, San Francisco, an investigator with the Howard Hughes Medical Institute, and Director of Immunology at both Repligen Corp. and Cell Genesys, Inc. Dr. Davis received his Ph.D. in immunology from UCSF and completed his postdoctoral work at the University of Texas Southwestern Medical Center. He is the author of 37 publications and is an inventor on 12 issued patents.
Dr. Bob Young is a Professor of Chemistry and the Merck Frosst-British Columbia Leadership Chair in Pharmaceutical Genomics, Bioinformatics and Drug Discovery at Simon Fraser University and the Medicinal Chemistry Division Head at the Centre for Drug Research and Development in Vancouver, Canada. Dr. Young’s research focuses on the design and synthesis of small molecule probes to discover and validate biological drug targets, and the design of enzyme inhibitors, and receptor agonists and antagonists for the treatment of osteoporosis, inflammation, atherosclerosis, diabetes and cancer. Dr. Young is a Fellow of the Royal Society of Canada, a Fellow of the Chemistry Institute of Canada, and past President of the Canadian Society for Pharmaceutical Science. Dr. Young received his PhD from the University of British Columbia, and a DIC from Imperial College London. Before joining the faculty at SFU in 2007, Dr. Young was a Vice President at Merck Frosst in Montreal and acting site head of Merck & Co.’s neuroscience research laboratories at Terlings Park.